PFIZER LIMITED = QUARTERLY RESULTS = FOR Q/E NOV 2011 = IMPROVED PERFORMANCE

PFIZER LIMITED

STAND ALONE RESULTS

FOR Q/E 30 Nov 2010

PFIZER LIMITED has produced improved results for Q/e Nov. 2010

NET SALES :           at Rs.236 Cr – is up by 4.53% from  Q/e Aug’10; up by 11.07% from Q/e May’10; up by 16.4% from Feb’10; and up by 20.98% from Q/e Nov’09.

Profit from Operations : is Rs.46 Cr – down by 7.89% from Q/e Aug’10; up by 35.04% from Q/e May’10;  Down by 7.16% from Q/e Feb’10; and up by 61.62% from Q/e Nov’09.

Net Profit : at Rs.44 cr is higher by 2.59% from q/e Aug’10; higher by 25.63% from q/e May’10;            higher by 2.66% from Q/e Feb’10; and higher by 69.37% from Q/e Nov’09

Basic EPS      was Rs.14.6 in q/e Nov’10; Rs.14.24 in q/e Aug’10; Rs.11.63 in Q/e May’10; Rs.14.23 in Q/e Fev’10; and Rs.8.62 in Q/e Nov’09.

PE RATIO : Current Market price is Rs.1195. The annualized EPS could be around Rs.55. Hence, PE Ratio comes to 21.73

The company has declared an interim dividend of 125%.

The Company has decided to change the Current Financial Year of the Company from December 01, 2009- November 30, 2010 to a 16 month period from December 01, 2009 to March 31, 2011.

RESULTS IN FIGURES :

PFIZER	30-Nov-10	31-Aug-10	31-May-10	28-Feb-10	30-Nov-09
Net Sales	23584	22561	21233	20261	19494
Dif %1	236	4.53	11.07	16.4	20.98
Other Operating Income	2514	1109	1112	494	807
Incre./decre.in SIT / WIP	1787	-1517	-1234	1156	1186
Raw Materials	4036	6501	5720	4022	4557
Purchase of Traded Goods	2741	2042	2932	2604	534
Employees Cost	3946	4616	4973	2736	3248
Depreciation	241	249	222	229	213
Other Expenditure	8757	6796	6333	5064	7723
Total Expenditure	21508	18687	18946	15811	17461
Profit from Operations	4590	4983	3399	4944	2840
Dif %2	46	-7.89	35.04	-7.16	61.62
Other Income	2034	1591	2148	1548	1462
PB T	6593	6427	5423	6492	3859
Tax expense	2235	2179	1954	2247	1286
Net Profit	4358	4248	3469	4245	2573
Dif %3	44	2.59	25.63	2.66	69.37
Dividend (%)	125	-	-	-	125
Face Value.Rs	10	10	10	10	10
Paid Up Equity	2984	2984	2984	2984	2984
Basic EPS	14.6	14.24	11.63	14.23	8.62

ANNOUNCEMENTS

TO THE EXCHANGE

11-01-2011    Pfizer Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on January 11, 2011, declared an Interim Dividend of Rs. 12.50/- per Equity share of Rs. 10 each (125%) for the current financial year ending March 31, 2011 i.e. 16 months period commencing from December 01, 2009 to March 31, 2011. The said Interim Dividend shall be paid / dispatched on January 31, 2011.

11-01-2011    Pfizer Limited has informed the Exchange regarding the standalone Results for the period ended on 30-NOV-2010 as follows: Net Sales of Rs. 23584 lacs for period ending on 30-NOV-2010 against Rs. 19494 lacs for the period ending on 30-NOV-2009. Net Profit / (Loss) of Rs. 4358 lacs for the period ending on 30-NOV-2010 against Rs. 2573 lacs for the period ending on 30-NOV-2009.    -

24-11-2010    Pfizer Limited has informed the Exchange that the Board of Directors of the Company has decided to change the Current Financial Year of the Company from December 01, 2009- November 30, 2010 to a 16 month period from December 01, 2009 to March 31, 2011, subject to the approval of the Registrar of Companies, Maharashtra, Mumbai under Section 210 (4). The Company has on November 23, 2010 made an application to the Registrar of Companies, Maharashtra, Mumbai, seeking approval for extension of the current Financial Year of the Company from December 01, 2009- November 30, 2010 to a 16 month period from December 01, 2009 to March 31, 2011.The subsequent Financial Years of the Company would be for the period April 01 to March 31. In view of the above, the Company will be publishing the quarterly Un-audited Financial Results for the quarters ended November 30, 2010 and February 28, 2011 within the required period in compliance with Listing Agreement. The Annual Financial Results of the Company will be prepared for a period of 16 months from December 01, 2009 to March 31, 2011.

*  *  *   E  N  D   *  *  *

PFIZER LTD = RESULTS FOR Q 3 / E AUG 2010 = MUCH IMPROVED PERFORMANCE

PFIZER Limited

NSE Symbol   PFIZER

REVIEW OF RESULTS OF Q3

Pfizer Ltd has declared the results for the 3^rd Qtr ending 31.08.2010. It’s accounting year is Dec – Nov.

Net Sales for q/e Aug,2010 is Rs.225.61 Cr. At this rate, likely sales for Y/e Nov,2010 will be Rs.866.16 Cr  – compared to Rs.771.60 for previous year (Non-consolidated). For this purpose Q1+Q2+Q3 are taken and for Q4, same level as Q3 is assumed.

On the same logic, Net Profit for Q3 is Rs.42.48 Cr and likely profit for Y/e Nov,2010 is Rs.162.10 Cr – against Rs.137.18 Cr for previous year.

Basic EPS   for Q3 is Rs.14.24 (Rs.11.63 for Q2 + Rs.14.23 for Q1) and the likely EPS for the Y/E Nov,2010 is Rs.54.34 – compared to Rs.45.97 for preceding Year.

Current Market Price is Rs.1117.The PE ratio is around 20.6.

The company’s amalgamation was done with Du Chem Labs. But, these results are non-consolidated results only. The results are evidently much better than the results of Y/e Nov,2009 and reflect considerable progress over the previous year.

RESULTS IN FIGURES:

PFIZER	2010 Aug	2010 May	2010 Feb	Q1+Q2+ Q3 +(Q3 for Q4)	DEC08-NOV09
Net Sales	22561	21233	20261	86616	77160
Other Operating Income	1109	1112	494	3824	2437
SIT & WIP	-1517	-1234	1156	-3112	961
Raw Materials	6501	5720	4022	22744	19867
Purchase of Traded Goods	2042	2932	2604	9620	7906
Employees Cost	4616	4973	2736	16941	12388
Depreciation	249	222	229	949	829
Other Expenditure	6796	6333	5064	24989	22651
Total Expenditure	18687	18946	15811	72131	64602
Profit from Operations	4983	3399	4944	18309	14995
Other Income	1591	2148	1548	6878	7101
Profit A I BB EI	6574	5547	6492	25187	22096
Exceptional Items	147	124	-	271	1092
Profit before tax	6427	5423	6492	24769	21004
Tax expense	2179	1954	2247	8559	7286
Net Profit after tax	4248	3469	4245	16210	13718
Net Profit	4248	3469	4245	16210	13718
Dividend (%)	-	-	-		125
Face Value .Rs	10	10	10	10	10
Paid Up Equity	2984	2984	2984	2984	2984
Basic EPS	14.24	11.63	14.23	54.34	45.97
Public holding (%)	29.25	29.25	29.25	29.25	29.25

ANNOUNCEMENTS

TO THE EXCHANGE

06-10-2010        Pfizer Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-AUG-2010 as follows: Net Sales of Rs. 22561 lacs for quarter ending on 31-AUG-2010 against Rs. 20484 lacs for the quarter ending on 31-AUG-2009. Net Profit / (Loss) of Rs. 4248 lacs for the quarter ending on 31-AUG-2010 against Rs. 4115 lacs for the quarter ending on 31-AUG-2009.      -

12-07-2010        Pfizer Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAY-2010 as follows: Net Sales of Rs. 21233 lacs for quarter ending on 31-MAY-2010 against Rs. 18585 lacs for the quarter ending on 31-MAY-2009. Net Profit / (Loss) of Rs. 3469 lacs for the quarter ending on 31-MAY-2010 against Rs. 3129 lacs for the quarter ending on 31-MAY-2009.

19-05-2010        News Verification : The media had reports that Pfizer Limited may buy a controlling stake in Piramal Healthcare Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Pfizer Limited has vide its letter inter-alia stated," We wish to inform you that as a policy we do not comment on market rumours and speculations."

25-02-2010        Pfizer Ltd. has informed the Exchange that the Board of Directors at its meeting held on February 25, 2010, recommended a Dividend of Rs. 12.50 per Equity Share of Rs.10/- each (125%) for the financial year ended November 30, 2009. 

25-02-2010        Pfizer Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 30-NOV-2009 as follows: Net Sales of Rs. 77227 lacs for year ending on 30-NOV-2009 against Rs. 68170 lacs for the year ending on 30-NOV-2008. Net Profit / (Loss) of Rs. 13712 lacs for the year ending on 30-NOV-2009 against Rs. 29958 lacs for the year ending on 30-NOV-2008.

BOARD MEETINGS

19-03-2010        The Company proposes to reconsider the audited Financial Results of the merged entity i.e. Pfizer Ltd. and Duchem Laboratories Ltd. A meeting of the Board of Directors of Pfizer Ltd. would be held on March 19, 2010, to reconsider and approve the Annual Financial Results of the merged entity with a view to give effect to the Court order.

*  *  *    E N D   *  *  *